AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ADDvise Group B

Prospectus Jul 11, 2025

8222_rns_2025-07-11_7d61be78-cd22-4932-a791-97e245f6dde9.pdf

Prospectus

Open in Viewer

Opens in native device viewer

ADDvise publishes prospectus and applies for admission to trading of bonds on Nasdaq Stockholm

11-07-2025 Regulatory press release

On 28 May 2025, ADDvise Group AB (publ) ("ADDvise") successfully issued senior unsecured bonds in an amount of SEK 800 million, under a total framework of SEK 1,600 million (the "Bonds").

Pursuant to the terms and conditions for the Bonds, ADDvise has undertaken to apply for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm. For this purpose, the company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the company's website www.addvisegroup.com and at the Swedish Financial Supervisory Authority's website www.fi.se. The application for admission to trading has been submitted and the first day of trading of the Bonds is estimated to be around 15 July 2025.

For further information, please contact:

Staffan Torstensson, CEO +46 70 433 20 19 [email protected]

Johan Irwe, CFO +46 73 731 26 11 [email protected]

About ADDvise Group

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.7 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Talk to a Data Expert

Have a question? We'll get back to you promptly.